- My News
- All News
- Most Popular
Allurion Technologies on Tuesday launched what it describes as a "transformed" weight-loss programme, featuring the company's flagship Elipse gastric balloon now rebranded as the Allurion balloon. The new Allurion programme also comprises a virtual-care suite, which includes a health tracker, connected scale and app, as well as an "insights" component that offers real-time patient analytics and telehealth features.
CEO Shantanu Gaur remarked that the launch represents "the culmination of an initiative we began over a year ago to reimagine the future of weight loss, and evolve from a company that offers a product to one that offers a revolutionary experience that delivers lifelong results."
The gastric balloon, which began commercial sales in 2016, is CE-marked in Europe, and is also available in the Middle East, Latin America and Asia. It is the first and only "procedureless" medical device that can help people shed 10% to 15% of their body weight in around 16 weeks, the company said.
In addition to the gastric balloon, Allurion noted that its weight-loss solution now combines "medical, digital, and nutritional approaches to jumpstart weight loss and form lifelong healthy habits." The company said the virtual-care suite, unveiled in January, comes with tools that enable a "360-degree weight-loss experience," with patient tracking and support functions, plus access to real-time data for healthcare teams to monitor progress.
To ensure you don't miss other Top Stories like these and news on key healthtech industry developments, sign up for our free daily e-newsletter here.
Did you like this article?